282 related articles for article (PubMed ID: 33815798)
1. Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders.
Alam W
SAGE Open Med; 2021; 9():20503121211002996. PubMed ID: 33815798
[TBL] [Abstract][Full Text] [Related]
2. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
Xu K; Wei Y; Giunta S; Zhou M; Xia S
Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
[TBL] [Abstract][Full Text] [Related]
3. Hypercoagulability in COVID-19: from an unknown beginning to future therapies.
Duca ŞT; Costache AD; Miftode RŞ; Mitu O; PetriŞ AO; Costache II
Med Pharm Rep; 2022 Jul; 95(3):236-242. PubMed ID: 36060499
[TBL] [Abstract][Full Text] [Related]
4. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).
Norooznezhad AH; Mansouri K
Microvasc Res; 2021 Sep; 137():104188. PubMed ID: 34022205
[TBL] [Abstract][Full Text] [Related]
7. Covid-19 and development of heart failure: mystery and truth.
Onohuean H; Al-Kuraishy HM; Al-Gareeb AI; Qusti S; Alshammari EM; Batiha GE
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2013-2021. PubMed ID: 34480616
[TBL] [Abstract][Full Text] [Related]
8. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
McConnell MJ; Kawaguchi N; Kondo R; Sonzogni A; Licini L; Valle C; Bonaffini PA; Sironi S; Alessio MG; Previtali G; Seghezzi M; Zhang X; Lee AI; Pine AB; Chun HJ; Zhang X; Fernandez-Hernando C; Qing H; Wang A; Price C; Sun Z; Utsumi T; Hwa J; Strazzabosco M; Iwakiri Y
J Hepatol; 2021 Sep; 75(3):647-658. PubMed ID: 33991637
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and Plasma Hypercoagulability.
Steadman E; Fandaros M; Yin W
Cell Mol Bioeng; 2021 Oct; 14(5):513-522. PubMed ID: 34221178
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 coagulopathy - what should we treat?
Chowdary P
Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235
[TBL] [Abstract][Full Text] [Related]
12. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
13. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 and Sepsis.
Koçak Tufan Z; Kayaaslan B; Mer M
Turk J Med Sci; 2021 Dec; 51(SI-1):3301-3311. PubMed ID: 34590796
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation.
Ward SE; Curley GF; Lavin M; Fogarty H; Karampini E; McEvoy NL; Clarke J; Boylan M; Alalqam R; Worrall AP; Kelly C; de Barra E; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Townsend L; Mallon PW; O'Sullivan JM; O'Donnell JS;
Br J Haematol; 2021 Feb; 192(4):714-719. PubMed ID: 33326604
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 and stroke: A review.
Qi X; Keith KA; Huang JH
Brain Hemorrhages; 2021 Jun; 2(2):76-83. PubMed ID: 33225251
[TBL] [Abstract][Full Text] [Related]
18. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
Obi AT; Barnes GD; Napolitano LM; Henke PK; Wakefield TW
J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):23-35. PubMed ID: 32916371
[TBL] [Abstract][Full Text] [Related]
19. Procoagulant Status and Fibrinolytic Activity in COVID-19 Patients during Illness and Convalescence.
Beznoshchenco OS; Romanov AY; Dolgushina NV; Gorodnova EA; Ivanets TY; Yarotskaya EL; Pyregov AV; Grachev SV; Sukhikh GT
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38255149
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of coronavirus infectious disease 2019-related neurologic diseases.
Klein RS
Curr Opin Neurol; 2022 Jun; 35(3):392-398. PubMed ID: 35283461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
